Seneca Biopharma, Inc., (NASDAQ: SNCA) is a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need. Seneca is in the process of finding and acquiring new assets, promising sciences and technologies that will provide meaningful therapies for patients.
As a first step in expanding our clinical stage pipeline, Seneca Bio and QYuns Therapeutics have signed a term sheet for global licensing of novel monoclonal antibodies for treating auto-immune diseases.